Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop...

Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to receive $160 million development...

1/24

Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)

2/24

Chiesi explores the impact of climate change on people living with respiratory conditions in the series “The Climate and Us”

3/24

ARCHIVE NEWS

Chiesi Group mid-year financial results demonstrate strong growth for 2023

10 Agosto 2023 NEWS

Inclusiveness, transparency and harmony: Chiesi Group introduces Human Rights Policy

03 Agosto 2023 NEWS

CHIESI’S SUSTAINABILITY REPORT 2022: A YEAR OF TANGIBLE ACHIEVEMENTS FOR PATIENTS, COMMUNITIES, AND THE PLANET

01 Agosto 2023 NEWS

Chiesi’s 2022 Sustainability Report: “Purpose First”

01 Agosto 2023 NEWS

Alessandro Chiesi appointed Chair of the Chiesi Group
Maria Paola Chiesi becomes the Vice Chair

18 Julho 2023 NEWS

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

23 Maio 2023 NEWS

2022 for Chiesi: The Group’s international growth continues

17 Abril 2023 NEWS

Skupina Chiesi in družba Affibody sodelujeta pri razvoju in trženju inovativnih oblik zdravljenja bolezni dihal

16 Março 2023 NEWS

Chiesi Group stands in solidarity with the people of #Turkiye and #Syria

09 Fevereiro 2023 NEWS

Chiesi appoints Giuseppe Accogli as new Group CEO

30 Janeiro 2023 NEWS

The Chiesi Group has undergone B Corp re-certification and set itself new, even more demanding operational goals until 2025

12 Outubro 2022 NEWS

The Chiesi Group monitors the implementation of measures for a healthier and more sustainable future

25 Julho 2022 NEWS

Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH

10 Maio 2022 NEWS

RARE IS NOT SO RARE: #WEWEARSTRIPES CAMPAIGN 2022 LAUNCHED TO MARK RARE DISEASE DAY

28 Fevereiro 2022 NEWS

Helping the World to Breathe - Chiesi Group among the protagonist of the ATS docuseries

30 Novembro 2021 NEWS

Chiesi accelerates path toward full sustainability despite Covid-19 pandemic

23 Junho 2021 NEWS

Chiesi Group calls for #ActionOverWords in the fight against climate change

10 Maio 2021 NEWS

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

22 Março 2021 NEWS

Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma

01 Fevereiro 2021 NEWS

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID- 19 pandemic

02 Abril 2020 NEWS

Chiesi Group Announces Establishment of New Global Rare Diseases Division

06 Fevereiro 2020 NEWS